Drug Trial Radar · NCT04188379
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Dec 16, 2019
Primary completion
Feb 3, 2022
Study completion Feb 3, 2022
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.
Conditions
- Primary Immune Thrombocytopenia
Interventions
efgartigimodBiological
Intravenous infusion of efgartigimod
PlaceboOther
Intravenous infusion of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.Time frame: From Week 19 up to Week 24
Locations
121 sites in 18 countries. Site status is shown where the registry gives one.
Investigator Site 0010038
Tucson, Arizona
Investigator Site 0010045
Washington D.C., District of Columbia
Investigator Site 0010034
Jacksonville, Florida
Investigator site 0010037
Ocala, Florida
Investigator Site 0010042
Iowa City, Iowa
Investigator Site 0010046
Greenville, North Carolina
Investigator Site 0010049
Cleveland, Ohio
Investigator Site 0010040
Columbus, Ohio
Investigator Site 0010041
Philadelphia, Pennsylvania
Investigator Site 0430004
Linz, Austria
Investigator Site 0430002
Vienna, Austria
Investigator Site 0430003
Vienna, Austria
Investigator Site 0320012
Brasschaat, Belgium
Investigator Site 0320011
Bruges, Belgium
Investigator Site 0320015
Leuven, Belgium
Investigator Site 0320014
Turnhout, Belgium
Investigator Site 0320020
Verviers, Belgium
Investigator site 0320002
Yvoir, Belgium
Investigator Site 3590001
Pleven, Bulgaria
Investigator Site 3590002
Sofia, Bulgaria
Investigator Site 4200001
Brno, Czechia
Investigator Site 4200008
Olomouc, Czechia
Investigator Site 4200006
Ostrava, Czechia
Investigator Site 4200007
Prague, Czechia
Investigator Site 0330019
Clermont-Ferrand, France
Investigator Site 0330009
Créteil, France
Investigator Site 0330015
Le Mans, France
Investigator Site 0330018
Montpellier, France
Investigator Site 0330016
Périgueux, France
Investigator Site 0330008
Pessac, France
Investigator Site 0330017
Rouen, France
Investigator Site 9950006
Tbilisi, Georgia
Investigator Site 9950007
Tbilisi, Georgia
Investigator Site 9950008
Tbilisi, Georgia
Investigator Site 9950009
Tbilisi, Georgia
Investigator Site 9950011
Tbilisi, Georgia
Investigator Site 9950012
Tbilisi, Georgia
Investigator Site 0490010
Düsseldorf, Germany
Investigator Site 0490008
Essen, Germany
Investigator Site 0490012
Giessen, Germany
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.